Form 4: Perrigo Executive Ronald Janish Reports Share Transactions

Sentiment:

SEC Form 4


Ronald Craig Janish, EVP at Perrigo, reports acquisition and disposal of ordinary shares on March 5, 2024, according to a Form 4 filing.

Summary

  • On March 5, 2024, Ronald Craig Janish, an Executive Vice President at Perrigo Company plc, reported transactions involving the company's ordinary shares.
  • Janish acquired 2,071 shares through the exercise of restricted stock units at a price of $27.26 per share.
  • Simultaneously, Janish disposed of 624 shares to cover tax obligations related to the vesting of the restricted stock units, also at $27.26 per share.
  • Additionally, Janish acquired 11,806 shares and disposed of 3,554 shares for an unspecified reason.
  • Following these transactions, Janish directly owns 29,890 ordinary shares.
  • The filing also includes a power of attorney granted in 2020, authorizing Todd W. Kingma, Ryan Bradtke, and Victor Torres to act on Janish's behalf for Section 16 filings.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing share transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance or outlook.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates the executive's transactions in company stock, which can be monitored by investors for insights into management's perspective on the company's value.

Comparison to Industry Standards

  • Form 4 filings are standard practice across all publicly listed companies in the US and are required by the SEC.
  • The transactions reported are typical for executives who receive stock-based compensation and periodically exercise options or RSUs.
  • Similar filings can be observed for executives at comparable companies in the healthcare and consumer goods sectors, such as Johnson & Johnson, Procter & Gamble, and Unilever.

Stakeholder Impact

  • The transactions may be of interest to shareholders as they provide insight into executive compensation and ownership.

Key Dates

DateDescription
2020-09-29Date of Power of Attorney execution.
2022-03-05Beginning of vesting period for Restricted Stock Units in 3 equal annual installments.
2024-03-05Date of share acquisition and disposal transactions.
2024-03-07Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.